Item 7.01 Regulation FD Disclosure.



In the first quarter of fiscal year 2022, we announced a change in
organizational structure designed to enable our growth strategies and strengthen
our focus on customers. Our chemistries and supplies business and our remarketed
instruments business will move from our Agilent CrossLab business segment to our
life sciences and applied markets business segment. Service revenue and cost of
sales related to the acquisition of BioTek will move from our life sciences and
applied markets business segment to our Agilent CrossLab business segment.
Following this reorganization, we will continue to have three business segments
(life sciences and applied markets, diagnostics and genomics and Agilent
CrossLab), each of which will continue to comprise a reportable segment.

We are furnishing this Current Report on Form 8-K to present selected segment information that reflect changes in our reportable segments related to the changes in our organizational structure. Beginning with the quarter ending January 31, 2022, our financial statements will reflect the new reporting structure with prior periods adjusted accordingly.



The information contained in this report, including Exhibit 99.1 attached
hereto, is being furnished and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of Section 18. Furthermore, the information contained in this
report shall not be deemed to be incorporated by reference into any registration
statement or other document filed pursuant to the Securities Act of 1933, as
amended.


Item 9.01.        Financial Statements and Exhibits.

(d) Exhibits

The following is furnished as an exhibit to this report and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended:

Exhibit No.                    Description

99.1 Selected segment information for the fiscal quarters ended January 31, 2019, 2020 and


                       2021, April 30, 2019, 2020 and 2021, July 31, 2019,

2020 and 2021 and October 31, 2019,


                       2020 and 2021 and fiscal years ended October 31,

2019, 2020 and 2021.


       104             Cover page interactive data file (embedded within

the Inline XBRL document)



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses